RFO
ZOM

RiverGlades Family Offices’s Zomedica Corp. ZOM Stock Holding History

RiverGlades Family Offices’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,900
Closed -$6K – 83
2021
Q3 		$6K Hold
10,900
– – ﹤0.01% 80
2021
Q2 		$9K Sell
10,900
-5,600
-34% -$5.22K 0.01% 79
2021
Q1 		$26K Buy
+16,500
New +$27K 0.02% 78

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PWMG
Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return

RiverGlades Family Offices's ZOM Position: Q4 2021 in Review

RiverGlades Family Offices sold out of Zomedica Corp. (ZOM) in Q4 2021, closing a stake of 10,900 shares — an estimated $6K sold.

RiverGlades Family Offices first reported a position in ZOM in Q1 2021 and held it in 3 quarters. The position peaked at $26K in Q1 2021. 107 funds tracked by Wall St. Rank hold ZOM as of Q4 2021.

  • RiverGlades Family Offices reported no remaining Zomedica Corp. position as of Q4 2021 after selling out during the quarter.
  • RiverGlades Family Offices sold 10,900 Zomedica Corp. shares in Q4 2021, an estimated $6K.
  • RiverGlades Family Offices first reported a position in Zomedica Corp. in Q1 2021 and held it in 3 quarters.
  • RiverGlades Family Offices's Zomedica Corp. position peaked at $26K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Zomedica Corp. as of Q4 2021.

Based on RiverGlades Family Offices's 13F filing for Q4 2021, filed 9 Feb 2022.